ABL-101
Acute Ischaemic Stroke (AIS)
Key Facts
About Aurum Biosciences
Aurum Biosciences is a Glasgow-based biotech developing the ABL-101 platform, an injectable oxygen carrier designed to treat oxygen deprivation in conditions like acute stroke. The lead asset has completed Phase 1/2a studies, with Phase 2 trials in stroke and inflammation imaging planned for 2026. As a spinout from NHS Greater Glasgow and Clyde, InnoScot Health, and the University of Glasgow, the company is targeting the vast unmet need in stroke, where only 10% of patients currently access effective therapeutics.
View full company profileAbout Aurum Biosciences
Aurum Biosciences is a Glasgow-based biotech developing the ABL-101 platform, an injectable oxygen carrier designed to treat oxygen deprivation in conditions like acute stroke. The lead asset has completed Phase 1/2a studies, with Phase 2 trials in stroke and inflammation imaging planned for 2026. As a spinout from NHS Greater Glasgow and Clyde, InnoScot Health, and the University of Glasgow, the company is targeting the vast unmet need in stroke, where only 10% of patients currently access effective therapeutics.
View full company profile